Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Heitner

Showing results (21-30 of 107) with videos related to

Pageof 11
Sort By:
Cardiovascular Ultrasound|September 18, 2022
Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathyPaola Roldan, Sriram Ravi, James Hodovan, et al.
JAMA Cardiology|September 16, 2020
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in HistoryAhmad Masri, Hongya Chen, Catherine Wong, et al.
Circulation. Cardiovascular Quality and Outcomes|October 26, 2018
Machine-Assisted Genotype Update System (MAGUS) for Inherited CardiomyopathiesNikolaos Papoutsidakis, Stephen B Heitner, Meghan C Mannello, et al.
BMJ Open|September 17, 2024
Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathySupriya Shore, Claire Ervin, Katherine Kosa, et al.
Clinical Pharmacokinetics|February 5, 2025
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenDonghong Xu, Justin D Lutz, Punag Divanji, et al.
Clinical Pharmacokinetics|August 23, 2025
Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenDonghong Xu, Justin D Lutz, Punag Divanji, et al.
Expert Review of Clinical Pharmacology|July 4, 2019
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosisMorie A Gertz, Morton Scheinberg, Márcia Waddington-Cruz, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 26, 2018
Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic CardiomyopathySuwen Kumar, Grace Van Ness, Aron Bender, et al.
Journal of Cardiac Failure|December 8, 2023
EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid CardiomyopathyAdam Castaño, Stephen B Heitner, Ahmad Masri, et al.
Clinical and Translational Science|April 9, 2025
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy ParticipantsNeha Maharao, Donghong Xu, Tyrell J Simkins, et al.
Pageof 11

Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
Cardiovascular Ultrasound|September 18, 2022
Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathyPaola Roldan, Sriram Ravi, James Hodovan, et al.
JAMA Cardiology|September 16, 2020
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in HistoryAhmad Masri, Hongya Chen, Catherine Wong, et al.
Circulation. Cardiovascular Quality and Outcomes|October 26, 2018
Machine-Assisted Genotype Update System (MAGUS) for Inherited CardiomyopathiesNikolaos Papoutsidakis, Stephen B Heitner, Meghan C Mannello, et al.
BMJ Open|September 17, 2024
Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathySupriya Shore, Claire Ervin, Katherine Kosa, et al.
Clinical Pharmacokinetics|February 5, 2025
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenDonghong Xu, Justin D Lutz, Punag Divanji, et al.
Clinical Pharmacokinetics|August 23, 2025
Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of AficamtenDonghong Xu, Justin D Lutz, Punag Divanji, et al.
Expert Review of Clinical Pharmacology|July 4, 2019
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosisMorie A Gertz, Morton Scheinberg, Márcia Waddington-Cruz, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 26, 2018
Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic CardiomyopathySuwen Kumar, Grace Van Ness, Aron Bender, et al.
Journal of Cardiac Failure|December 8, 2023
EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid CardiomyopathyAdam Castaño, Stephen B Heitner, Ahmad Masri, et al.
Clinical and Translational Science|April 9, 2025
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy ParticipantsNeha Maharao, Donghong Xu, Tyrell J Simkins, et al.
Pageof 11